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Introduction
Cisplatin (cis-diammine-dichloroplatinum) (Cispt) is 
one of the inorganic platinum-based chemotherapeutic 
and most widely used for the treatment of various types 
of cancers, including head and neck, prostate gland, 
liver, breast, cervix, uterus cancer and hepatocarcinoma, 
because this drug prevents cancer cells from dividing 
further (Panesso et al., 2014; Song et al., 2014; Singh et 
al., 2015). The discovery of Cispt was a breakthrough 
that triggered the interest in metal-containing 
compounds as potential anticancer drugs (Florea and 
Büsselber, 2011). However, various side effects, such as 
nephrotoxicity, nausea and vomiting, myelosuppression, 
immunosuppression and neurotoxicity, have been 
observed with Cispt therapy that cause its clinical use to 
be limited (Panesso et al., 2014; Shah and Dizon, 2009; 
Tsang et al., 2009). Although Cispt is one of the most 
commonly used anticancer agent (Lee et al. 2015), it is 
unstable in aqueous solutions (Sewell, 2010). The main 
form of this drug decomposition is displacement of the 
chloride ligand (Cubells et al., 1993). Cispt is frequently 
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prepared in sodium chloride infusion. To prevent potential 
precipitation, the drug keeps at room temperature. In 
addition, chemical stability of the drug depends upon 
pH and sunlight. The preferable pH for maintaining the 
chemical structure of Cispt ranges between 3.5 and 5.5. 
Furthermore, the drug is somewhat sensitive to light 
(Sewell, 2010).
Escherichia coli (E. coli) is the type species of 
the genus Escherichia. The bacteria contain mostly 
motile gram-negative bacilli that fall within the family 
Enterobacteriaceae (Haddad Kashani et al., 2017; Stenutz 
et al., 2006). Also, E. coli is facultatively anaerobic, 
rod-shaped bacterium is commonly found in lower 
intestine of warm-blooded organisms (endotherms) 
(Singleton, 2004). E. coli is an important cause of urinary 
tract infections, enteric infections and systemic infections, 
such as bacteremia, nosocomial pneumonia, cholecystitis, 
cholangitis, peritonitis, cellulitis, osteomyelitis and 
infectious arthritis in humans (Jalali et al., 2016; Kashani 
and Moniri 2015; Mandell, 2000; Pitout, 2012). It is also 
leading cause of neonatal meningitis (Kashani et al., 2018; 
Pitout, 2012). 
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This study aimed to evaluate cisplatin efficacy on 
HepG2 and E. coli cells under an acidic condition.
Materials and Methods
Cell lines and chemical agents
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) (0.5 mg/mL) and Cispt were 
obtained from Sigma Company (Sigma, USA). Dulbecco’s 
modified Eagle’s medium (DMEM) was purchased from 
Invitrogen (USA). Isopropanol and Hydrogen chloride 
(HCl) were obtained from Merck (Germany) and 
Zhechem (China), respectively. All other materials were 
of analytical grade. De-ionized water was used all through 
the study. HepG2 cell line and E. coli strain were supplied 
by Pasteur Institute of Iran, Tehran.
Preparation of acidic Cispt
To prepare acidic Cispt, 2 mg of Cispt in powder form 
(standard Cispt) was dissolved in 1 mL HCl 0.01 N. After 
one month, solvent phase was evaporated and Acidic Cispt 
in was obtained again.
Evaluating the acidic Cispt by using FTIR method
For this purpose, the acidic Cispt was dried in room 
temperature, mixed with bromide potassium and then 
pressed to prepare the tablet. Next, the tablet was analyzed 
by FTIR (Nicolet 740SX FTIR spectrophotometer with 
an MCT-B detector (USA)).
Determination of MIC
MIC is the lowest concentration of an antimicrobial 
agent capable to halt the growth of a microorganism 
(Kashani et al., 2012; Hosseini et al., 2016). For this 
purpose, 100 μL Luria Broth bacteria culture medium 
was introduced in 96-well plates. Acidic Cispt, standard 
Cispt and bacterial suspension were then added. Next, the 
plate was incubated at 37°C for 24 h. The bacterial growth 
was determined as absorbance raise by Elisa reader (Bio 
Tek Instruments, VT, USA) at 600 nm. The experiment 
repeated three times (Panghal et al., 2011; Ferdosian et 
al. 2015).
In vitro cytotoxicity of the Cispt
The cytotoxicity of the standard and acidic Cispt 
was determined by MTT assay in HepG2 cell line on 
96-well plates. Cells were seeded in dilution rate of 
1×104 for each well in DMEM containing 10% Fetal 
Bovine Serum (FBS), 2 mM glutamine, and antibiotics 
(60 mg/L penicillin G, 100 mg/L streptomycin, 50 µL/L 
amphotericin B) (37oC, 5% CO2). They were allowed to 
attach for 48 h. The culture media were then removed and 
cells were treated with the standard and acidic Cispt at the 
concentrations of 160, 80, 40, 20 and 0 µM. After 24 h 
incubation, the drug containing culture was removed and 
100 µL MTT solutions (0.5 mg/mL, pH 7.4) was added 
to each well and incubated for 3 h at 37oC. Later, MTT 
was discarded and 100 µL isopropanol 100% was added 
to dissolve the formazan crystals. Next, absorbance was 
read at 540 nm using spectrophotometric method. Finally, 
IC50 was measured by statistical package Pharm-PCS 
software, and cell viability (V) was calculated as in Eq. 1 
(Sanganeria et al., 2015).
Cell viability (%) = sample absorbance/control 
absorbance×100
Statistical analysis
The results of MIC assay were analyzed by using 
Excel program and are expressed as mean with standard 
deviation. In addition, the results of MTT assay were 
analyzed by one-way ANOVA and T-test and the 
significance level was set at p < 0.05 (Lotfi et al. 2016; 
Piroozmand et al. 2017). For this purpose, SPSS version 
19.00 software (SPSS, Chicago, IL, USA) was used.
Results
Preparation of acidic Cispt
Cispt powder was effortlessly derived from the acidic 
solution. From the morphological point of view, Cispt kept 
the color and solidity as parent compound. The difference 
results between standard and acidic Cispt in MTT assay 
was not statistically significant (p = 0.15).
Figure 1. FTIR Spectrum of Acidic Cispt. The figure shows the Cispt-related peaks which kept in acidic condition. 
The results showed that the acidic Cispt preserved its chemical structure. Also, chemical bonds of acidic Cispt were 
approximately equal to those of standard Cispt.
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Results of the study indicated the stability of the drug 
for 14 days in all storage containers: polypropylene bags 
(100.1 ± 0.5%), glass bottles (99.7 ± 0.3%), polyethylene 
bags (98.9 ± 1.0%) and PVC bags (104.6 ± 1.0%).
Rochard et al., (1992) prepared the concentration of 
0.5 and 0.9 mg/ml of Cispt and located into ambulatory 
infusion pumps constructed from ethylene-vinyl acetate 
at 22°C and 35°C for 28 days. The results of the study 
confirmed the stability of Cispt in the both concentrations.
In the present study, we prepared Cispt in acidic 
solution at pH 2. Acidic Cispt was provided in the 
concentration of 2 mg/mL without difficulty. Cispt in 
acidic solution kept the appearance perfectly. FTIR results 
also confirmed that the chemical structure of Cispt was 
remained intact. The efficacy of Cispt was evaluated with 
MTT and MIC assays. Cytotoxicity results confirmed 
Cispt kept the efficacy under acidic conditions after one 
month. MIC results also demonstrated acidic Cispt has 
potency as compare as parent compound. This study is 
highlighted with the simplicity of evaluation methods 
for examine the drug efficacy which is reported for first 
time. Comparison the efficacy of acidic solution derived 
Cispt with the typical form of Cispt in sodium chloride 
infusion could be suggested as future work. Finally, the 
results of the study indicated that acidic conditions at pH 
2 not only did not have detrimental effects on the stability 
of Cispt but also kept its efficacy approximately compared 
to parent Cispt.
In conclusion, Cispt is one of the frequently used 
anticancer drug for various malignancies. However, Cispt 
instability has considered as a drawback for the clinical 
use. Enhancing the stability of Cispt could improve the 
efficacy of the drug. So, as a solution, in this research, 
Cispt was incubated in acidic conditions. MTT and MIC 
techniques were used to evaluate the cytotoxicity and 
bactericidal effects of Cispt, respectively. FTIR method 
was used to determine the chemical structure of the drug 
as well. The study showed that keeping Cispt in acidic 
condition could be regarded for preserving the Cispt 
potency against degradation and moreover keeping the 
functionality of the drug for therapeutic purposes.
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